Tempus ECG-AF vs EchoGo Core
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tempus ECG-AF is designed to predict the risk of future atrial fibrillation by analyzing 12-lead ECGs, targeting patients 65 or older without pre-existing AF. In contrast, EchoGo Core automates the analysis of echocardiograms to provide precise measurements for current cardiac diagnosis, such as LV function. While both are AI-powered cardiology tools, they utilize different diagnostic modalities and address distinct clinical questions, making them adjacent rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Tempus ECG-AF is an FDA-cleared AI algorithm that analyzes 12-lead ECGs to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter within 12 months, supporting earlier identification and follow-up. EchoGo Core is an FDA-cleared, AI-powered platform that automates echocardiogram analysis, providing precise measurements for confident cardiac diagnosis and improved patient outcomes.
Tempus ECG-AF analyzes 12-lead ECG recordings. EchoGo Core analyzes echocardiograms to provide automated left ventricular analysis, including Ejection Fraction (EF), Global Longitudinal Strain (GLS), and LV volumes.
Tempus ECG-AF has CMS reimbursement available with CPT codes 0764T and 0765T, with a Medicare rate of $128.90 effective January 1, 2025. EchoGo Core is subscription-based, typically per analysis or through flexible pay-per-scan models, and its cardiac strain analysis is reimbursable.
Tempus ECG-AF is intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, to detect signs associated with new onset AF. EchoGo Core is indicated for use in adult populations for quantification and reporting of cardiovascular function to support physician diagnosis.
Tempus ECG-AF provides results indicating an increased risk or no increased risk of new onset AF within 12 months, to be interpreted with other clinical information. EchoGo Core provides automated measurements for LV analysis, including EF, GLS, and LV volumes, with zero inter- and intra-variability and rapid report generation.